Literature DB >> 17387224

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.

Sridhar Vempati1, Carola Reindl, Seshu Kumar Kaza, Ruth Kern, Theodora Malamoussi, Martin Dugas, Gudrun Mellert, Susanne Schnittger, Wolfgang Hiddemann, Karsten Spiekermann.   

Abstract

FLT3-internal tandem duplications (FLT3-ITDs) comprise a heterogeneous group of mutations in patients with acute leukemias that are prognostically important. To characterize the mechanism of transformation by FLT3-ITDs, we sequenced the juxtamembrane region (JM) of FLT3 from 284 patients with acute leukemias. The length of FLT3-ITDs varied from 2 to 42 amino acids (AAs) with a median of 17 AAs. The analysis of duplicated AAs showed that in the majority of patients, the duplications localize between AAs 591 to 599 (YVDFREYEY). Arginine 595 (R595) within this region is duplicated in 77% of patients. Single duplication of R595 in FLT3 conferred factor-independent growth to Ba/F3 cells and activated STAT5. Moreover, deletion or substitution of the duplicated R595 in 2 FLT3-ITD constructs as well as the deletion of wild-type R595 in FLT3-ITD substantially reduced the transforming potential and STAT5 activation, pointing to a critical role of the positive charge of R595 in stabilizing the active confirmation of FLT3-ITDs. Deletion of R595 in FLT3-WT nearly abrogated the ligand-dependent activation of FLT3-WT. Our data provide important insights into the molecular mechanism of transformation by FLT3-ITDs and show that duplication of R595 is important for the leukemic potential of FLT3-ITDs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387224     DOI: 10.1182/blood-2006-10-053181

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  The Future of Targeting FLT3 Activation in AML.

Authors:  Mark B Leick; Mark J Levis
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 2.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Authors:  Mark Levis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 3.  Resistance to targeted therapies: delving into FLT3 and IDH.

Authors:  Sai Prasad Desikan; Naval Daver; Courtney DiNardo; Tapan Kadia; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2022-06-09       Impact factor: 9.812

Review 4.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 5.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

6.  Structural and numerical variation of FLT3/ITD in pediatric AML.

Authors:  Soheil Meshinchi; Derek L Stirewalt; Todd A Alonzo; Titus J Boggon; Robert B Gerbing; Jennifer L Rocnik; Beverly J Lange; D Gary Gilliland; Jerald P Radich
Journal:  Blood       Date:  2008-02-27       Impact factor: 22.113

Review 7.  Structural and functional alterations of FLT3 in acute myeloid leukemia.

Authors:  Soheil Meshinchi; Frederick R Appelbaum
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

8.  Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.

Authors:  Song-Bai Liu; Qiao-Cheng Qiu; Xie-Bing Bao; Xiao Ma; Hong-Zhi Li; Yue-Jun Liu; Su-Ning Chen; Yao-Hua Song; De-Pei Wu; Sheng-Li Xue
Journal:  Cancer Sci       Date:  2018-11-14       Impact factor: 6.716

9.  Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients.

Authors:  Takahiko Koyama; Kahn Rhrissorrakrai; Laxmi Parida
Journal:  BMC Cancer       Date:  2019-02-01       Impact factor: 4.430

10.  Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Authors:  Frank G Rücker; Ling Du; Tamara J Luck; Axel Benner; Julia Krzykalla; Insa Gathmann; Maria Teresa Voso; Sergio Amadori; Thomas W Prior; Joseph M Brandwein; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Lynn Savoie; Jorge Sierra; Celine Pallaud; Miguel A Sanz; Joop H Jansen; Dietger Niederwieser; Thomas Fischer; Gerhard Ehninger; Michael Heuser; Arnold Ganser; Lars Bullinger; Richard A Larson; Clara D Bloomfield; Richard M Stone; Hartmut Döhner; Christian Thiede; Konstanze Döhner
Journal:  Leukemia       Date:  2021-07-28       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.